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Abstract. Using surface plasmon resonance (SPR) and 
electrospray mass spectro  metry (ESI-MS), proinsulin 
C-peptide was found to influence insulin-insulin inter-
actions. In SPR with chip-bound insulin, C-peptide 
mixed with analyte insulin increased the binding, while 
alone C-peptide did not. A control peptide with the same 
residues in random sequence had little effect. In ESI-MS, 
C-peptide lowered the presence of insulin hexamer. The 
data suggest that C-peptide pro  motes insulin disaggrega-
tion. Insulin/insulin oligomer μM dissociation constants 
were determined. Compatible with these findings, type 1 
diabetic patients receiving insulin and C-peptide devel-
oped 66% more stimula  tion of glucose metabolism than 
when given insulin alone. A role of C-peptide in promot-
ing insulin disaggregation may be important physiologi-
cally during exo  cytosis of pancreatic β-cell secretory 
granulae and pharmacologically at insulin injection sites. 
It is compatible with the normal co-release of C-peptide 
and insulin and may contribute to the bene  ficial effect of 
C-peptide and insulin replacement in type 1 diabetics.
Keywords. Surface plasmon resonance, electrospray ionization mass spectrometry, insulin effect, diabetes type 1, 
proinsulin C-peptide, insulin disaggregation, insulin hexamer decrease.
C-peptide, the connecting peptide of proinsulin, plays an 
important role in the bio  syn  thesis of insulin. It serves as 
a linker between the B and A chains of insulin, facili  tat-
ing appropriate folding and formation of the insulin SS 
bridges [1–3]. C-peptide also exerts physiological effects 
and shows the char  ac  teristics of a bioactive peptide. It 
binds specifically at nanomolar concentra  tions to cell 
membranes [4], appears to be associated with G-protein-
coupled effects, resulting in activation of Ca2+ [5] and 
MAP-kinase [6–8] -dependent intracellular signal  ling. 
In  sulinomimetic effects of C-peptide have also been ob-
served [9]. C-pep  tide stimu  lates Na+,K+-ATPase and 
endothelial nitric oxide synthase activities [10–12]. Glo-
merular hyper  filtra  tion and albumin excretion in urine of 
diabetes type 1 patients or in animal models of type 1 
diabetes are diminished by C-peptide administration [13, 
14]. Likewise, C-peptide therapy results in amelioration 
or reversal of diabetes-induced functional and structur  al 
abnormalities of peripheral nerves [15]. Many molecular 
inter  actions and clinical effects of C-peptide have been 
documented [16, 17]. In spite of all this evidence, an in-
dependent action of C-peptide has not been generally ac-
cepted. This is explained by several facts, including the 
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high species varia  bility of C-peptide in a manner atypical 
of many hormones [8] and the absence of reports of a 
receptor for C-peptide.
Recently, we studied molecular interactions between 
C-peptide and specific proteins using surface plasmon 
resonance (SPR). The use of SPR in tracing C-peptide 
binding prompted us to use this technique in studies of C-
peptide inter  actions with insulin. These results, together 
with mass spectrometric findings and clinical results in 
patients with type 1 diabetes form the basis of the present 
report.
Materials and methods
Insulin and C-peptide were covalently linked to Biacore 
CM5 chips with both N- and C-terminal attachments, fol-
lowing the procedures given by the chip manufacturer. 
Human insulin (Actrapid, Novo Nordisk, Denmark) was 
used after desalting on NAP 10 columns. Human C-pep-
tide and scrambled (same composition with different, 
random sequence) C-peptide were from Sigma Genosys 
(Cambridge, UK). For the C-terminal attach  ments, sur-
face thiol coupling up to 5000 response units (RU) was 
used, and for the N-terminal attachment, amine coupling 
up to 1000 RU, in both cases with proper de  activa  tions 
and controls as given by the manufacturer. For compari-
son, an insulin analogue preparation (Humalog; Eli Lilly, 
Fegersheim, France) with a residue exchange to give a 
rapid-acting insulin was used, also after prior desalting 
on NAP 10 columns. 
Interaction analyses were performed with a Biacore 3000 
instrument at a flow rate of 20 μl/min at pH 3–7 (10 mM 
Na citrate for pH 3, 4 and 5; 10 mM bis-Tris for pH 6; 
10 mM Tris/HCl for pH 7), all buffers containing 100 mM 
NaCl and 0.005% SP20. All Biacore data were analysed 
with the Bia evaluation software 4.1. Addi  tional models 
for curve-fit calculations were constructed in IGOR Pro 
(version 4.01.A, WaveMetrics). 
For mass spectrometry, the data were acquired on a Q-
TOF Ultima API instrument (Waters, Milford, Mass.) 
equipped with the standard Z-spray source, operated in 
the positive-ion mode under the control of MassLynx 4.1 
between 700–3500 m/z with a rate of 5 scans/s. Samples 
were introduced via a nanoflow electro  spray interface 
from metal-coated borosilicate glass capillary needles 
(Proxeon Bio  systems, Odense, Denmark). The source 
temperature was 80 °C. Conditions were set with a capil-
lary voltage at 1.6 kV, cone and RF Lens 1 energies of 90 
and 50 V , respectively, and a source pressure of 6.0 × 10–5 
mbar with the use of collision gas. Both insulin and C-
peptide solutions were prepared as 600  μM solutions 
in H2O/HCl, pH 5, insulin after desalting as mentioned 
above, and extensive dialysis against this solu  tion. Diffe-
rent sample concentrations were prepared by dilution of 
the stock solution in H2O/HCl, pH 5.
For effects in diabetic patients, nine type 1 diabetes pa-
tients (clinical characteristics in Table  1) were studied 
on 2 separate days with at least 1 week in between, and 
four patients were studied on a third occasion. Besides 
insulin they had no medica  tion. All were informed of 
the purpose, nature and possible risks of the study be-
fore giving consent to participate, and the study proto-
col was approved by an ethics committee. The patients 
were admitted to the hospital the evening before the study 
and main  tained on intravenous low-dose insulin during 
the night. The insulin infusion was so adjusted that the 
blood glucose was in the range of 4–7 mM in the morn-
ing. At about 8 a.m., the insulin infusion was stopped and 
20 min later a subcutaneous injection of either a mixture 
of insulin (10 U Humulin; Eli Lilly, Indianapolis, Ind.) 
and C-peptide (60 nmol, recombinant human C-peptide; 
Eli Lilly), or insulin (10 U) alone was given in random-
ized double-blind fashion. On a third occasion, insulin 
(10 U) and C-peptide (60 nmol) were given simultane-
ously but in two separate subcutaneous depots, one on 
each side of the abdomen. The injec  tions were given with 
an automatic injection device (standardized for speed and 
Table 1. Individual clinical data for the patients.
Patient
No.
Sex
(F, M)
Age
(years)
BMI
(kg/m2)
Diabetes duration
(years)
Insulin dose
(U/kg per 24 hours)
HbA1c
1
(%)
1 M 46 29.9 31 0.95 5.2
2 M 28 21.9 13 0.78 7.7
3 M 32 24.3 12 0.89 6.8
4 F 29 26.0 15 0.40 9.9
5 F 23 26.7 12 0.76 6.1
6 F 29 20.6 11 0.70 5.8
7 F 35 22.5 22 0.75 5.1
8 F 34 21.2 20 0.80 6.5
9 M 31 26.3 17 0.63 8.3
1 Reference normal value < 4%. All patients were C-peptide negative (< 0.20 nmol/l).Cell. Mol. Life Sci.    Vol. 63, 2006  Research Article       1 8 0 7
depth) 100 mm laterally of the umbilicus into the middle 
of the sub  cutaneous tissue layer, the depth of which was 
determined with ultrasound. Plasma glucose concentra-
tions were measured every 5 min throughout the study. 
The level was allowed to decrease to 3.5 mM and then 
maintained in the range 3.5–5.0 mM by variable glucose 
infusion [18]. Plasma glucose was measured using a glu-
cose oxidase method on a Beckman Glucose Analyzer 2 
(Beckman, Fullerton, Calif.). Insulin concentrations were 
determined using a radioimmuno  assay. Standard statis-
tical methods were employed using the Student t-test 
(paired and unpaired) when applicable. Data are pre-
sented as average values ± SE.
Results
Using insulin and C-peptide preparations, we studied the 
effects of C-peptide on insulin-insulin interactions mea-
sured with SPR and electrospray ionization mass spec-
trometry (ESI-MS). Similarly, with the glucose clamp 
technique, we evaluated the effects on whole-body glu-
cose utilization by addition of C-peptide to injected insu-
lin in diabetic patients.
SPR analysis of insulin-insulin interactions. Insulin in 
solution interacts with insulin molecules immobilized on 
the dextran sur  face of Biacore CM5 chips. Curves ob-
tained (Fig. 1) are similar, differing only with the attach-
ment loads of the chips used, independent of whether the 
chip-bound insulin is attached by N- or C-terminal cou-
pling. Insulin-insulin interactions were studied at analyte 
concentrations of 0.025–10 μM and were optimal with 
least back  ground at pH 5. After background subtraction 
and averaging (over three injections per concentration) of 
the responses, the sensorgrams fitted best (using least-
squares global curve fitting with IGOR Pro; Fig. 1b) to a 
model of an analyte with two binding sites competing for 
one binding site on the ligand. This model applies also for 
the condition where either analyte or ligand (of one bind-
ing site each), due to variations in conformations, give 
rise to two kinetically distinguishable interaction paths. 
Accordingly, two apparent equilibrium dissociation con-
stants were obtained, one with a KD of 2.71 μM and an-
other with a KD of 4.65 μM (with a relatively slow and 
quick dissociation rate, respectively). Similar attempts at 
derivation of other binding models (one to one, one to 
one followed by a conformational change, or a dynamic 
di  mer-binding model) failed to fit the sensorgrams ob-
tained. These results show that the insu  lin-insulin interac-
tions can be studied by SPR.
The interactions were greatly affected by the pH of the 
solution and somewhat by the presence of Zn ions (inhib-
iting at concentrations above 1× analyte), or Zn chelators 
(optimal at EDTA 5× analyte concentration, non-satura-
tion at lower excess, and inhibitory at higher excess). In-
sulin Humalog (Eli Lilly), a human insulin analogue with 
a structural part exchanged to Lys-Pro (instead of Pro-Lys 
in insulin) favouring a monomeric nature under physi-
ological conditions [19], was also tested. The analogue 
showed weak interactions when used as analyte over a 
surface with the same analogue immobilized. It also gave 
only little interaction with native insulin, both when the 
analogue was in the soluble flow-through over human in-
sulin on the chip (N-terminally attached) and when the 
arrangement was the oppo  site. This shows that the SPR 
binding characteristics agree with known properties of 
human insulin and insulin analogues.
SPR analysis of C-peptide influences on insulin-insu-
lin interactions. Initially, we attempted to find C-pep-
tide-insulin interactions by applying C-peptide or insu  lin 
as the surface-bound ligand (attachment in either direc-
tion) and the other partner in the ana  lyte position (the 
flow-through) over a wide concentration range (10 pM 
to 10 μM). In no case did we find evidence for binding 
interactions. These results showed that C-peptide and 
insulin appear to have no strong binding in the insulin 
form(s) present on the chip under the SPR conditions. 
This form(s) is likely to be mainly monomeric for three 
reasons: first, pretreatments are strongly dissociative; 
second, ESI-MS (see below) of C-peptide-insulin mix-
tures show few heterodimers; third, addition of insulin 
to the analyte in SPR (see below) shows an effect of C-
peptide not present without the insulin addition. Hence, 
C-peptide is concluded to lack a strong binding site for 
monomeric insulin. This conclu  sion is compatible with 
the fact that C-peptide and insulin are joined in proinsulin 
by co  valent bonds rather than binding attachments, and 
with little ordered structure in the C-peptide part [20, 21]. 
We also tested binding of C-peptide in solution to chip-
bound C-peptide and found no evi  dence for such bind-
Figure 1. SPR binding curves of insulin with insulin at pH 5 in 
solution at concentrations of 0.05, 0.1, 0.2, 0.5 and 1 μM (from bot-
tom to top) over a surface with insulin immobilized by N-terminal 
(a) and by C-terminal (b) attachment. Each curve is the average of 
three injections in random order and after blank subtraction (dot-
ted curves). The superimposed curves show the results of global 
fitting and a perfect match with a model having an analyte with 
two binding sites and a chip-bound immobilized ligand with one 
binding site.1808       J.  Shafqat  et  al.  Proinsulin  C-peptide  disaggregates  insulin  oligomers
ing either. This appears relevant, since C-peptide is very 
negative (– 5 charges), with high repulsive forces.
However, C-peptide, mixed with insulin in solution, in-
fluenced the insulin-insulin interactions measured above. 
A 1- to 5-fold C-peptide excess over insulin analyte in-
creased the observable SPR binding signal (Fig. 2a), and 
this effect was reproducible over a considerable con-
centration interval. It was quite specific for C-peptide, 
not being shown to any appreciable extent by scrambled 
C-peptide (Fig. 2b). The new curve obtained in the pres-
ence of C-peptide did not fit into the standard model fit-
tings (see above). Presumably, therefore, the extra inter-
action observed in the presence of C-peptide and insulin 
may involve oligomer states of insulin and binding inter-
actions of C-peptide with such states. Whether the criti-
cal C-peptide binding oligomers are insulin hexamers or 
lower oligomers is difficult to evaluate from just the SPR 
data. However, the disappearance of insulin hexamers in 
the presence of C-peptide upon ESI-MS analysis (see be-
low) suggests that C-peptide binding to analyte insulin 
hexamers in SPR causes their disaggregation and hence 
an increase in insulin monomers with resulting increased 
binding to the chip-ligand. An effect via C-peptide bind-
ing to insulin dimers appears possible looking just at the 
SPR data, but would anyway suggest C-peptide physi-
ological effects via the insulin hexamer since it is a trimer 
of dimers [22]. In considering insulin-C-peptide binding 
interactions, segment similarities between C-peptide and 
parts of insulin [M. Henriksson, J. Johansson, T. Moede, 
I. Leibiger, J. Shafqat, P. O. Berggren and H. Jörnvall, 
unpublished data] may be of interest. Time and tempera-
ture had some, but limited, effects on the binding curves. 
Thus, higher temperature (37 °C instead of 25 °C) in-
creased the insulin-insulin binding. C-peptide appeared 
to slightly reduce the rate of dissociation. In conclusion, 
C-peptide appears to influence insulin oligomer-forming 
capacity and to some extent oligomer stability.
We also tested C-peptide analogues. The C-terminal pen-
tapeptide, pre  vious  ly shown to replace C-peptide effects in 
several assays [4, 5, 7, 8, 10], also stimu  lated SPR-measur-
able binding when mixed with insulin in the flow-through 
solu  tion, while a Glu27Ala C-peptide analogue, inactive in 
the assays, did not stimulate the SPR signal in the presence 
of insulin. Two other analogues with Glu to Ala replace-
ments (at positions 3 and 11), previously found to be more 
active in one assay [8] than the 27 replacement, also gave a 
greater SPR signal increase with insulin than did the posi-
tion 27 analogue. In conclusion, much of the C-peptide in-
fluence on insulin oligomers seems to be associate with the 
presence of Glu27, whether in the C-ter  minal pentapeptide 
fragment or in the entire C-peptide. Hence, the importance 
of Glu27 appears to be correlated with the C-peptide effect 
on the SPR-measurable binding to insulin oligomers.
C-peptide influences hexamer insulin states observed 
in ESI-MS analysis. Bind  ing interactions for insulin and 
other proteins can also be studied by mass spectromet  ry 
[23]. We therefore tested the insulin solutions and the in-
sulin/C-peptide mixtures by direct inlet in ESI-MS analy-
sis. The patterns obtained were complex, with a mixture 
of ion charge states, and in each case with several Na+ and 
K+ adducts, but three obser  va  tions were clear.
The first was that C-peptide in ESI-MS shows the pres-
ence of many ion adducts. This is consistent with its 
highly negative charge and is also well-known in analy-
ses of other peptides. The adduct formations easily over-
shadow patterns from the presence of oligomeric forms 
at low abundance, and the strength of ESI-MS is not to 
distinguish differential effects between C-peptide and its 
similarly charged analogues but rather to trace effects on 
insulin oligomers, especially hexamers. Nevertheless, at 
low peptide concentrations, C-peptide showed slightly 
more effects on insulin than scrambled C-peptide. The 
second observa  tion is that several low-abundance insu-
lin oligomers were observed (dimers, trimers) in addition 
to the clearer hexamers, and at high C-peptide concen-
trations, C-peptide dimers and even insulin-C-  peptide 
hetero  dimers. Third, and most consistent, the presence 
of hexamer signals at different charge states in the ESI 
Figure 2. SPR binding curves of insulin at pH 5 alone in solution 
(dashed lines) and mixed in solution with a 5-fold excess of C-
peptide (grey lines) (a) and scrambled C-peptide (b), over a surface 
with insulin immobilized at the C-terminal. Insulin concentrations 
used were 1, 5, 10 and 20 μM (from bottom to top), each curve be-
ing the average of three runs and after blank subtraction.Cell. Mol. Life Sci.    Vol. 63, 2006  Research Article       1 8 0 9
mass spectra markedly decreased from their level in insu-
lin solutions to an absence in insulin-C-peptide mixtures 
(Fig. 3). Hence, ESI-MS analysis suggests that C-peptide 
depolymerizes the hexameric aggregates of insulin.
Effect on glucose utilization of C-peptide additions to 
insulin injected to type 1 diabetic patients. The insu-
lin-induced increase in whole-body glucose utilization 
after subcutaneous injection of either insulin plus C-pep-
tide or insulin alone was evaluated using the glucose 
clamp technique. The combined injection of equimolar 
amounts of insulin and C  -peptide required a glucose in-
fusion that tended to be of longer duration (158 ± 25 vs 
123 ± 28 min) and greater magnitude (+ 66%, p < 0.01) 
than the corresponding values after injection of insulin 
alone (Fig. 4). In another set of experiments, insulin and 
C-peptide were injected either in the same or in separate 
subcutaneous abdominal depots, approximately 20  cm 
apart. When C-peptide and insulin were ad  ministered 
in the same depot, the reduction in plasma glucose was 
significantly faster (0–60 min, p < 0.02) than when the 
two were administered in separate depots (Fig. 5a). Insu-
lin appeared more rapidly in the circulation and in larger 
amounts (AUC 0–360 min, p < 0.05) compared with the 
corresponding data after injection into separate depots 
(Fig. 5b). The amount of glucose infused to avoid hypo-
glycaemia had to be increased by 129% (p < 0.01) when 
insulin and C-peptide were administered in the same 
depot compared with when separate depots were used, 
and the duration of the infusion was longer (186 ± 24 vs 
117 ± 37 min, p < 0.02).
Figure 3. Nano-ES mass spectra of insulin (30 μM, lower panel) and mixture of insulin and C-peptide at 1:1 ratio (both at 30 μM, upper 
panel) at pH 5. The charge states labelled with M, D, T and H in Roman represent identified monomers, dimers, trimers and hexamers, 
respectively, of insulin, in italics, those identified for C-peptide, and in lower case letters, those for a C-peptide-insulin heterodimer. Unla-
belled peaks represent variable ion adducts of C-peptide oligomers that were not easily interpreted. The peaks after m/z 2100 are shown at 
magnification ×20 in both panels. The lower panel shows the presence of insulin hexamers at 12+,13+, 14+ and 15+ charge states, while the 
upper panel shows their absence at equimolar co-presence of C-peptide.
Figure 4.  Glucose concentrations (left scale) and glucose infu-
sion rates (right scale) after subcutaneous injection of C-peptide 
(60 nmol) plus insulin (10 U) (filled diamonds, hatched area) or in-
sulin alone (10 U) (open squares, white area) in nine type 1 diabetes 
patients. The glucose infusion required to prevent hypoglycaemia 
was 66% greater (p < 0.01) after subcutaneous injection of insulin 
plus C-peptide compared with insulin alone.1810       J.  Shafqat  et  al.  Proinsulin  C-peptide  disaggregates  insulin  oligomers
Discussion
This study measures C-peptide effects on insulin under 
three highly divergent con  ditions, in solution versus a 
solid-phase chip-bound partner, in gas phase, and in pa-
tients. Although each set of experiments has restrictions 
complicating interpreta  tions (different oligomeric states, 
different phases and in part unknown surface effects in 
the SPR experiments; unclear significance of gas phase 
interactions in ESI-MS; non-molecular interaction studies 
in the patients), all three experimental sets show C-pep-
tide influences on insulin effects. This consistency appears 
relevant. The com  bined SPR and ESI-MS data show that 
C-peptide influences insulin-insulin inter  actions affecting, 
in particular, oligomeric states, and in ESI-MS decreasing 
hexameric signals. As obvious from the presence of several 
oligomers, there should be many separate interaction con-
stants. Two were estimated by curve fitting to bind ing mod-
els in the SPR experiments, both in the micromolar range. 
In that range, inter  actions are not likely to occur in serum 
or tissues, but are of interest in relation to insulin secretion 
in the pancreas of healthy individuals and at the injection 
sites of diabetic subjects. Thus, the possibility should be 
considered that a physiological effect of C-peptide may 
be its contribution to the formation of insulin monomers 
follow  ing exocytosis of the secretory granule content of 
hexameric insulin into the pancreatic extra  cellular space. 
Such a C-peptide function is compatible with the physio-
logical co-release of C-peptide and insulin. C-peptide may 
also affect insulin oligo  meric states and disaggregation at 
subcutaneous sites of insulin injection in diabetic patients. 
Conse  quently, we con  clude that C-peptide may increase 
the bioavailability of insulin.
Consistent with this conclusion from the molecular stud-
ies, the present patient data show that co-injection of C-
peptide and insulin makes insulin appear more rapidly 
in the circulation and enhances its stimulatory effect 
on glucose utilization. Combined, all three results are 
compatible with a pre  vious report concerning insulin 
and C-peptide co-administration by continuous-rate sub-
cutaneous infusion for 1 month in pa  tients with type 1 
diabetes; this resulted in improved glycaemic control and 
lowered insulin requirements [24]. The possibility may 
be con  sidered that C-peptide enhances insulin absorp-
tion also by stimulation of local nitric oxide release [12], 
resulting in increased subcutaneous blood flow. A major 
C-peptide-induced circulatory effect appears less likely, 
though, since intravenous, as distinct from sub  cutaneous, 
co-infusion of insulin and C-peptide in patients with type 
1 diabetes results in a more rapid onset and more marked 
hypo  glycaemia than infusion of insulin alone [25]. Thus, 
the clinical findings appear to provide support for the mo-
lecular ob  servations that disaggregation of hexa  meric in-
sulin is facilitated in the presence of C-peptide, resulting 
in enhanced insulin action. We conclude from the three 
sets of studies performed here that C-peptide adminis-
tered in addition to insulin may be beneficial in the treat-
ment of type 1 diabetes.
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